DP9 effectively disrupts the interaction between EGFR and Gal-3, and suppresses the Gal-3/EGFR/AKT/FOXO3 signaling pathway, thereby exerting anti-pancreatic cancer activity. This evidence concerns the gene FOXO3 and pancreatic neoplasm.